MedTrace Logo

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

NCT04833764 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-10-15

No results posted yet for this study

Summary

The goal of this study is to determine the safety and tolerability or efficacy of adjunctive treatments (including rosuvastatin 20 mg daily) in combination with standard anticoagulation therapy (Factor Xa inhibitors) in patients with lower extremity deep vein thrombosis (DVT). The efficacy of adjunctive treatments to prevent the development of post thrombotic syndrome (PTS) after DVT will be evaluated.

Conditions

  • Post-thrombotic Syndrome
  • Deep Vein Thrombosis Leg

Interventions

DRUG

Rosuvastatin

Oral administration of 20 mg rosuvastatin for at least 3 months

Sponsors & Collaborators

  • Khanh Nguyen

    lead FED

Principal Investigators

  • Khanh P Nguyen, MD · Portland VA Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-06-01
Completion
2025-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833764 on ClinicalTrials.gov